Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 245 | $191.38 | $46,887.78 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 12 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.84 to $191.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 252 | $190.10 | $47,904.82 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 11 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.62 to $190.45, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 164 | $189.06 | $31,006.64 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 10 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.51 to $189.46, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 164 | $187.08 | $30,681.43 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 9 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,190 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.71 to $187.40, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 1,075 | $185.73 | $199,664.80 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 8 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.46 to $186.10, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 145 | $184.59 | $26,766.17 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 7 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,429 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.46 to $184.82, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 256 | $183.35 | $46,936.78 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 6 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,574 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.01 to $183.57, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 171 | $181.86 | $31,098.59 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 5 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,830 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.66 to $182.25, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
SaleCommon Stock | 168 | $181.09 | $30,422.77 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 4 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,001 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.50 to $181.39, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 2,062 | $5.95 | $12,268.90 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 3 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 416 | $46.00 | $19,136.00 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 2 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 22:10 UTC |
Herrmann John A IIIEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 416 | $27.60 | $11,481.60 |
DisclosureSEC source: 0001209191-21-023613 · doc4.xml · nonDerivative · entry 1 Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · derivative · entry 10 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2029-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Plan vested one (1) year from the December 12, 2019 grant date. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · derivative · entry 9 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Plan vested one (1) year from the December 15, 2017 grant date. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
Exercise / conversionCommon Stock | 37,500 | $3.99 | $149,437.50 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · nonDerivative · entry 6 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
Exercise / conversionCommon Stock | 10,000 | $27.60 | $276,000.00 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · nonDerivative · entry 5 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · derivative · entry 8 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested one (1) year from the December 13, 2018 grant date. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
SaleCommon Stock | 2,446 | $229.41 | $561,134.17 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · nonDerivative · entry 4 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.00 to $229.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
SaleCommon Stock | 3,120 | $228.42 | $712,661.35 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · nonDerivative · entry 3 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,446 F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.00 to $228.89, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
SaleCommon Stock | 4,434 | $227.43 | $1,008,435.26 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · nonDerivative · entry 2 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,566 F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.00 to $227.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 22:41 UTC |
YOUNG JAMES FDirector
|
Exercise / conversionCommon Stock | 10,000 | $46.00 | $460,000.00 |
DisclosureSEC source: 0001209191-21-023076 · doc4.xml · nonDerivative · entry 1 YOUNG JAMES F · CIK 0001219864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 21:33 UTC |
MCMANUS MICHAEL A JRDirector
|
SaleCommon Stock | 3,000 | $220.57 | $661,710.00 |
DisclosureSEC source: 0001209191-21-022613 · doc4.xml · nonDerivative · entry 2 MCMANUS MICHAEL A JR · CIK 0001051997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,951 Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 21:33 UTC |
MCMANUS MICHAEL A JRDirector
|
SaleCommon Stock | 1,000 | $221.40 | $221,400.00 |
DisclosureSEC source: 0001209191-21-022613 · doc4.xml · nonDerivative · entry 1 MCMANUS MICHAEL A JR · CIK 0001051997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,951 Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 129 | $225.89 | $29,139.90 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 24 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.50 to $226.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 375 | $224.78 | $84,291.94 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 23 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,940 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.37 to $225.26, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 164 | $223.86 | $36,713.20 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 22 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,315 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.31 to $224.26, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 60 | $221.91 | $13,314.60 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 21 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,479 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 180 | $219.84 | $39,571.79 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 20 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,539 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.45 to $220.15, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 114 | $218.53 | $24,911.91 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 19 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,719 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.37 to $218.68, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 402 | $217.31 | $87,357.21 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,833 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.80 to $217.71, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 421 | $216.05 | $90,955.37 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,235 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.73 to $216.41, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 459 | $215.19 | $98,770.88 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,656 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.73 to $215.70, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 57 | $213.01 | $12,141.71 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,115 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.00 to $213.02, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 57 | $211.96 | $12,081.56 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.94 to $211.97, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 17, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 5 | $210.85 | $1,054.25 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,229 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Appreciation Right · Derivative | 4,819 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · derivative · entry 29 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 Underlying: Common Stock · 4,819 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · kind: The reporting person received 2,423 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 132 shares of common stock underlying the stock appreciation rights representing the base value and 2,264 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 15, 2021 of $217.46. F21 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,124 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · derivative · entry 28 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,752 Underlying: Common Stock · 3,124 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F20 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,101 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · derivative · entry 27 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,322 Underlying: Common Stock · 1,101 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F19 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 868 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · derivative · entry 26 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605 Underlying: Common Stock · 868 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 619 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · derivative · entry 25 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,861 Underlying: Common Stock · 619 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · derivative.exercise_date: Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of Novavax, Inc.'s common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Novavax, Inc.'s common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 2,918 shares were cancelled. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Tax withholdingCommon Stock | 2,264 | $217.46 | $492,329.44 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,234 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · kind: The reporting person received 2,423 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 132 shares of common stock underlying the stock appreciation rights representing the base value and 2,264 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 15, 2021 of $217.46. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Disposition to issuerCommon Stock | 132 | $217.46 | $28,704.72 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,498 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · kind: The reporting person received 2,423 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 132 shares of common stock underlying the stock appreciation rights representing the base value and 2,264 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 15, 2021 of $217.46. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 4,819 | $217.46 | $1,047,939.74 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · kind: The reporting person received 2,423 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 132 shares of common stock underlying the stock appreciation rights representing the base value and 2,264 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 15, 2021 of $217.46. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 100 | $201.47 | $20,147.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 1,282 | $200.14 | $256,585.76 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,911 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.84 to $200.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 1,490 | $199.07 | $296,616.09 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,193 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.68 to $199.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 1,939 | $197.87 | $383,662.37 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,683 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.54 to $198.24, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
SaleCommon Stock | 901 | $196.88 | $177,388.79 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,622 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.27 to $197.23, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 3,124 | $5.95 | $18,587.80 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:35 UTC |
Glenn Gregory MPresident, R&D
|
Exercise / conversionCommon Stock | 1,101 | $46.00 | $50,646.00 |
DisclosureSEC source: 0001209191-21-021525 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.